[Gly21]-beta-Amyloid (1-40), A21G, Flemish Mutation – 0.5 mg

Overview

The [Gly21]-beta-Amyloid (1-40), A21G, Flemish Mutation is a specialized peptide implicated in Alzheimer’s Disease research. This variant of beta-amyloid demonstrates a unique characteristic by showing a low tendency to aggregate compared to other forms, while still resulting in gradual deposit formation within vessel walls. This property makes it particularly relevant for studies focused on the mechanisms behind Alzheimer’s disease pathology.

Key Features

• Low aggregation tendency, reducing experimental complications
• Progressive deposit formation in vessel walls, mimicking Alzheimer’s pathology
• Specifically composed of A-beta 1-40, providing relevance to familial Alzheimer’s research
• Available in a convenient 0.5 mg format for various experimental applications
• Quality controlled for consistent results in biochemical assays

Specifications

FAQ

What is the significance of the A21G mutation?

The A21G mutation in beta-amyloid plays a critical role in understanding the diverse pathological mechanisms of Alzheimer’s disease. It offers an alternative pathway of aggregation and deposition that is essential for studying the disease’s progression.

How should I store the peptide?

For optimal stability, store the [Gly21]-beta-Amyloid peptide at -20°C. This will help maintain its integrity and effectiveness for experimental use.

Can this peptide be used for in vivo studies?

While this peptide is primarily utilized for in vitro studies due to its specific characteristics, it can provide valuable insights that may inform in vivo research directions related to Alzheimer’s disease pathology.

Explore other peptides in our catalog, such as PKG Substrate or Autocamtide-2to complement your research on neurological indicators and disease mechanisms.

Related Products

• CREBtide [KRREILSRRPSYR], 5-FAM labeled

Browse more in Peptides.